Back to Search
Start Over
Safety of dose escalation by simultaneous integrated boosting radiation dose within the primary tumor guided by 18FDG-PET/CT for esophageal cancer.
- Source :
-
Radiotherapy & Oncology . Feb2015, Vol. 114 Issue 2, p195-200. 6p. - Publication Year :
- 2015
-
Abstract
- Purpose To observe the safety of selective dose boost to the pre-treatment high 18 F-deoxyglucose (FDG) uptake areas of the esophageal GTV. Methods Patients with esophageal squamous cell carcinoma were treated with escalating radiation dose of 4 levels, with a simultaneous integrated boost (SIB) to the pre-treatment 50% SUVmax area of the primary tumor. Patients received 4 monthly cycles of cisplatin and fluorouracil. Dose-limiting toxicity (DLT) was defined as any Grade 3 or higher acute toxicities causing continuous interruption of radiation for over 1 week. Results From April 2012 to February 2014, dose has been escalated up to LEVEL 4 (70 Gy). All of the 25 patients finished the prescribed dose without DLT, and 10 of them developed Grade 3 acute esophagitis. One patient of LEVEL 2 died of esophageal hemorrhage within 1 month after completion of radiotherapy, which was not definitely correlated with treatment yet. Late toxicities remained under observation. With median follow up of 8.9 months, one-year overall survival and local control was 69.2% and 77.4%, respectively. Conclusions Dose escalation in esophageal cancer based on 18 FDG-PET/CT has been safely achieved up to 70 Gy using the SIB technique. Acute toxicities were well tolerated, whereas late toxicities and long-term outcomes deserved further observation. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 01678140
- Volume :
- 114
- Issue :
- 2
- Database :
- Academic Search Index
- Journal :
- Radiotherapy & Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 101340810
- Full Text :
- https://doi.org/10.1016/j.radonc.2014.12.007